Clinical Trial

A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes

Withdrawn Phase 2
View on ClinicalTrials.gov →
Summary
This study is being done to look at how well a study medicine called CagriSema helps people with diabetes lower their blood sugar. In this study the sponsor will compare two version of CagriSema injected by two different types of injection devices. Which treatment participants get is decided by chance. CagriSema is still being tested in studies and is not yet available for doctors to prescribe. The study will last for about 38 weeks.
Protocol Amendment History 4 changes
critical Trial status changed: NOT_YET_RECRUITING → WITHDRAWN 2026-07-10
critical Reason stopped changed: — → The study is withdrawn due to strategic reasons. 2026-07-10
notable Enrollment reduced: 400 -> 0 participants 2026-07-10
notable Trial sites expanded: 47 -> 61 locations 2026-03-31
Trial Details
NCT Number NCT07357740
Lead Sponsor Novo Nordisk A/S
Conditions Diabetes Mellitus, Type 2
Start Date 2026-08-27
Primary Completion 2027-08-25 (estimated)
Study Completion 2027-10-13 (estimated)
Updated on ClinicalTrials.gov 2026-07-09